Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of
pharmacotherapeutic interventions in a variety of indications, with currently more than 40 …

There are many factors that can influence the pharmacokinetics (PK) of a mAb or Fc-fusion
molecule with the primary determinant being FcRn-mediated recycling. Through Fab or Fc …

Most of oral targeted therapies are tyrosine kinase inhibitors (TKIs). Oral administration
generates a complex step in the pharmacokinetics (PK) of these drugs. Inter-individual PK …

Nivolumab is a fully human monoclonal antibody that inhibits programmed death‐1
activation. The clinical pharmacology profile of nivolumab was analyzed by a population …

This book approaches the subject from a mechanistic perspective that pitches the language
at a level that is understandable to those entering the field and who are not familiar with its …

Abstract The US Food and Drug administration (FDA) has approved several polyclonal
antibody preparations and at least 18 monoclonal antibody preparations (antibodies …

The objectives of the following investigation were (1) development of a physiologically
based pharmacokinetic (PBPK) model capable of characterizing the plasma and tissue …

Antibodies have proven to be effective agents in cancer imaging and therapy. One of the
major challenges still facing the field is the heterogeneous distribution of these agents in …

Intravitreal administration is the method of choice in drug delivery to the retina and/or
choroid. Rabbit is the most commonly used animal species in intravitreal pharmacokinetics …

In the development of cancer chemotherapy, besides the discovery of new anticancer drugs,
a variety of nanocarrier systems for the delivery of previously developed and new …